09:00-09:25
Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan
Motoko Yamaguchi (Mie University Graduate School of Medicine, Japan)
09:25-09:50
Research Progress of NK/ T-Cell Lymphoma: Experience from China
Huangming Hong (Sichuan Cancer Hospital, China)
09:50-10:15
Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
[SS14] Scientific Session 14: Germline Variants and Hematologic Malignancies: Current Understanding and Clinical Implications
Discovery Hall
March 28 (Sat), 09:00-10:15
TBD
09:00-09:25
Clonal Evolution from Germline to Malignancy: Timing and Mechanisms
Jyoti Nangalia (University of Cambridge, UK)
09:25-09:50
Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management
Marc H.G.P. Raaijmakers (Erasmus MC Cancer Institute, The Netherlands)
09:50-10:15
Germline Predisposition Genes in Lymphoid Malignancies
Susan L. Slager (Mayo Clinic, USA)
[SS15] Scientific Session 15: Exploring the Map of CML: Beyond BCR::ABL1
Universe Arena
March 28 (Sat), 09:00-10:15
TBD
09:00-09:25
Immunological Landscape of CML
Kyung-Mi Lee (Korea University College of Medicine, Korea)
09:25-09:50
Integrating Biomarkers to Predict Response to TKIs
Sin Tiong Ong (Duke-NUS Medical School, Singapore)
09:50-10:15
Drug Combination to Overcome Resistance
Delphine Rea (Hôpital Saint-Louis, France)
[ES07] Education Session 07: Preventive and Supportive Approaches in Hematologic Malignancies
Supernova Stage
March 28 (Sat), 09:00-10:15
TBD
09:00-09:25
Vaccination and Infection Prevention
Seong Jin Choi (Seoul National University College of Medicine, Korea)
09:25-09:50
Cardiotoxicity: Risk Assessment and Prevention
Hyukjin Park (Chonnam National University Medical School, Korea)
09:50-10:15
Chemotherapy-induced Peripheral Neuropathy
Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea)
[PL03] Plenary Lecture 03
Galaxy Theater & Discovery Hall
March 28 (Sat), 10:30-11:15
TBD
10:30-11:15
High-risk Multiple Myeloma in 2026: Early Intervention, MRD-driven Therapy, and Beyond
Philippe Moreau (University Hospital of Nantes, France)